Literature DB >> 3876941

The effects of cyclosporin on lymphocyte activation in a systemic graft-vs.-host reaction.

P M Chisholm, M T Drayson, J H Cox, W L Ford.   

Abstract

We have investigated the effects of cyclosporin (CsA) on each of three stages of lymphocyte activation in vivo viz. sequestration of alloantigen-reactive lymphocytes from the circulation into the spleen and lymph nodes, blast transformation and induction of DNA synthesis in the activated cells and release of these cells and their progeny into the circulation. Parental strain lymphocytes injected i.v. into semi-allogeneic rats and recovered from the thoracic duct within 36 h are profoundly unresponsive in a local graft-vs.-host assay to the alloantigens of the F1 hybrid but have normal activity against unrelated alloantigens (negative selection). CsA treatment of the F1 hybrid recipients did not prevent this selective sequestration of antigen-reactive cells. In the untreated F1 hybrid, from 36 h after injection, large numbers of dividing blast cells were released into the lymph. These cells did not appear in the lymph of recipients treated with CsA. However, CsA did not prevent the activation of cells sequestered in the spleen or lymph nodes as assessed by [3H] thymidine incorporation and autoradiography. This unexpected finding suggests that CsA inhibits lymphocyte responses to alloantigens in vivo after DNA synthesis which is a later stage than the in vitro studies have shown.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876941     DOI: 10.1002/eji.1830151018

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Randomised double blind controlled trial of cyclosporin in multiple sclerosis.

Authors:  P Rudge; J C Koetsier; J Mertin; J O Mispelblom Beyer; H K Van Walbeek; R Clifford Jones; J Harrison; K Robinson; B Mellein; T Poole
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

2.  Oral administration of cyclosporin does not prevent expansion of antigen-specific, gut-associated, and spleen lymphocyte populations during Chlamydia trachomatis proctitis in nonhuman primates.

Authors:  M Zeitz; T C Quinn; A S Graeff; R Schwarting; S P James
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

Review 3.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

4.  Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation.

Authors:  Koichi Araki; Shivaprakash Gangappa; Dirck L Dillehay; Barry T Rouse; Christian P Larsen; Rafi Ahmed
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

5.  Preventive and therapeutic effects of cyclosporin and valine2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.

Authors:  C Feurer; L H Chow; J F Borel
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

6.  Lymphokine gene expression in vivo is inhibited by cyclosporin A.

Authors:  A Granelli-Piperno
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.